


Timing and Extension of Amputation In Anal Carcinoma

Coloproctology, Bern Jan 22, 2011



NICOLAS DEMARTINES, MD, FACS, PROFESSOR AND CHAIRMAN
UNIVERSITY HOSPITAL CHUV LAUSANNE, SWITZERLAND

www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Terminology: anal canal cancer

Epidermoid

- Below dentate line
 - squamous CC
- At and above dentate line
 - « basaloid », « cloacogenic », or « transitional »
 - = non keratinizing types of squamous cell carcinoma

} same
ttt

www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Terminology: Anal margin cancer

Anal margin cancer ≠ Anal canal cancer

Other histology

- Adenocarcinoma (= rectum cancer)
- Melanoma,
- Lymphoma
- Merkel carcinoma
- Sarcoma

} other
ttt

www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Anal Cancer Prognosis (Multi-modal treatment +/- surgery)

Stage :	5 year overall survival:
• T1: (≤2cm)	68.5%
• T2: (2-5 cm)	58.9%
• T3: (>5 cm)	43.1%
• T4: (adj. organ invasion)	34.3%

Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A. Outcomes and prognostic factors for squamous cell carcinoma of the anal canal: analysis of patients from the National Cancer Database. Dis Colon Rectum 2009;52:624-31
www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Anal Cancer Prognosis (Multi-modal treatment +/- surgery)

Stage :	5 year overall survival:
• T1: (≤2cm)	68.5%
• T2: (2-5 cm)	58.9%
• T3: (>5 cm)	43.1%
• T4: (adj. organ invasion)	34.3%
• N0:	62.9%
• N+:	37.4%
• M0:	59.4%
• M+:	18.7%

Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A. Outcomes and prognostic factors for squamous cell carcinoma of the anal canal: analysis of patients from the National Cancer Database. Dis Colon Rectum 2009;52:624-31
www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Treatment

clinical practice guidelines Anal. #001099-01 (Supplément à #01-100-0000
du 03/08/2009/0000000171)

Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

R. Gyntje-Jones¹, J. M. A. Northover², S. A. Cienski³
On behalf of the ESMO Guidelines Working Group⁴

- Anal Margin T1 No : **Primary surgery** (≠ anal canal)
- All other: **Chemoradiation**
 - 45-50 Gy during 5 weeks, including inguinal areas
 - Combined with 5-FU and Mitomycin C during week 1 and 5

www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Assessment of response to Chemoradiation

- **First assessment at 6-8 weeks**
 - Clinical (DRE, inguinal), (+/- biopsies: controversial)
 - PET CT: predicts long term outcome
 - MRI: tends to overestimate disease

www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Assessment of response to Chemoradiation

- First assessment at 6-8 weeks
 - Clinical (DRE, inguinal), (+/- biopsies: controversial)
 - PET CT: predicts long term outcome
 - MRI: tends to overestimate disease
- **60-85%: complete clinical response (CR)**
- **5-30%: >50% CR: follow*, +/- boost crxtt**
- **≈10%: <50% CR: immediate salvage surgery**

(*SCC continue to decrease in size for 3 to 12 weeks following therapy)

www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Indications to surgery: local failure of (chemo-)radiation

- A. progression or <50% response at 6-8 weeks
- B. residual disease at final assessment and after boost/salvage radiation
- C. recurrence after initial complete clinical response

www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
Rehnan AG et al., BJS 2004

Indications to surgery: local failure of (chemo-)radiation

- A. progression or <50% response at 6-8 weeks
- B. residual disease at final assessment and after boost/salvage radiation
- C. recurrence after initial complete clinical response

Table 4 Pathways to local disease failure and proportions salvaged

	Radiotherapy alone		Chemoradiotherapy	
	n	LDF*	n	LDF*
All patients	127	60 (47.2)	127	38 (30.7)
Initial treatment response				
Complete response, no booster	7	0	7	0
Complete response, after booster	89	29	104	23
Incomplete response, after booster	18	15	10	10
Partial response < 50% or progression, before booster	13	13	6	6

Values in parentheses are percentages of number of patients treated and local disease failures (LDFs).

www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
Rehnan AG et al., BJS 2004

Salvage surgery & survival

www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
Rehnan AG et al., BJS 2004

Salvage surgery & survival

Table 5 Surgical treatment of local residual or recurrent disease and other failures

	Total (n = 254)	Radiotherapy (n = 127)	Chemoradiotherapy (n = 127)
Residual or recurrent local disease			
APR*	67	41	26
Total pelvic clearance	3	1	2
Local excision	3	2†	1
Palliative care for local disease failure			
Colostomy only	2	2	0
No surgery	24	14‡	10
Other major operation			
APR for treatment-related complications	38	3	0
Negative laparotomy (suspicion of recurrence)	1	1	0
Failure to close pre-treatment colostomy	7	2	5
Total no. of colostomies	84 (33.1)	50 (39.4)	33 (26.0)
Total failure (disease and other)	110 (43.3)	66 (52.0)	44 (34.6)

www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
Rehnan AG et al., BJS 2004

Outcomes of salvage surgery

Author, year, institution	Curative, n	Interval	Median OS (months)	5-year OS (%)
Renehan ²⁰ , 2005, Manchester	73	1988-2000	42	40
Akbari ¹¹ , 2004, MSKCC	47	1980-2001	49	40
Schiller, 2007, Toronto	40	1988-2006	41	39
Ghouri ²⁶ , 2005, Marseille	36	1987-2002	-	69
Nilsson ¹⁷ , 2002, Stockholm	35	1985-2000	-	52
Ferenschild ¹⁶ , 2005*, Rotterdam	18	1985-2000	27	30
Bai ²⁷ , 2004, Beijing	16	1978-1994	16	-
Papacostantinou ²¹ , 2006, Minnesota	15	1992-2002	-	-
Van der Wal ¹⁹ , 2001, Johns Hopkins	13	1980-1998	33	47

*Included SCC and adenocarcinoma.

Schiller D et al (Toronto), Ann Surg Oncol 2007

Predictors of successful salvage

	n	Postsalvage survival at 3 years (%)*	P‡
Resection margins positive			
No	55	61.4 (44.8, 74.3)	
Yes	7	0	0.008
Type of disease failure			
Residual (≤ 3 months)	12	30.9 (5.1, 63.0)	
Recurrent (> 3 months)	61	59.1 (43.6, 71.7)	0.023
Nodal involvement			
No	52	59.1 (42.1, 72.6)	
Yes	10	31.8 (4.9, 64.7)	0.070

Renehan AG et al. (NHS UK), BJS 2004
Akbari R et al. (MSKCC), DCR 2004
Schiller D et al (Toronto), Ann Surg Oncol 2007

- ### Predictors of successful salvage
- R0
 - Recurrent > residual
 - N0
 - Female gender
 - Low Charlson comorbidity score
 - Size of resected tumor <4cm
- Renehan AG et al. (NHS UK), BJS 2004
Akbari R et al. (MSKCC), DCR 2004
Schiller D et al (Toronto), Ann Surg Oncol 2007

Original article

Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer

A. G. Renehan¹, M. P. Saunders², P. F. Schofield¹ and S. T. O'Dwyer¹


Departments of ¹Surgery and ²Clinical Oncology, Christie Hospital NHS Trust, Manchester, UK
Correspondence to: Mr A. G. Renehan, Department of Surgery, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK (e-mail: arenehan@picr.man.ac.uk)



Diseases of the Colon & Rectum

Oncologic Outcomes of Salvage Surgery for Epidermoid Carcinoma of the Anus Initially Managed With Combined Modality Therapy

Robert P. Akbari, M.D.,¹ Philip B. Paty, M.D.,¹ Jose G. Guillem, M.D.,¹ Martin R. Weiser, M.D.,¹ Larissa K. Temple, M.D.,¹ Bruce D. Minsky, M.D.,² Leonard Saltz, M.D.,³ W. Douglas Wong, M.D.¹

¹ Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
² Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York
³ Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York






Surgery 2011 for Anal Cancer

TME: Total Mesorectal Excision
APR: Abdomino Perineal Resection

www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS



Laparoscopic Approach

Anatomical landmarks


- ▶ Presacral plane
- ▶ Hypogastric nerves
- ▶ Denonvilliers fascia & Prostate
- ▶ Seminal vesicles
- ▶ Pelvic plexus
- ▶ Levator ani muscles

www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Laparoscopic Rectum Surgery: Surgical anatomy

- Double fascia of Denonvilliers
 - Anterior leaflet of the fascia is related to the prostate
 - Posterior leaflet is related to the rectum
- Space of Proust between anterior and posterior leaflet
- "It is not always easy to find the passage between wind and water"

www.chirurgieviscerale.ch Healey JE Jr, Hodge J. Surgical Anatomy (2nd ed). Toronto: BC Decker, 1990, p. 262.
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS



Laparoscopic Rectum Surgery Surgical anatomy

Denonvilliers
Charles-Pierre
French anatomist and surgeon
Paris 1808-1872

www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Closure or tissue transfer?

- Perineal Wound Complication (23% - 80%)
- Risk factors
 - Diabetes, obesity, smoke
 - **Radiotherapy** :
Wound complication: ↑ From 23% to 47%

Wiatrek, Clin colon rectal Surg, 2008, 21:76-85
Bullard, Dis Colon rectum 2005, 48:438-43
Khoo, Surgery 2001, 130:463-9

www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Closure or tissue transfer?

	<u>Primary</u>	<u>Flap</u>
• Pelvic abscess	46%	12%
• Primary wound healing	33%	63%

Wiatrek, Clin colon rectal Surg, 2008, 21:76-85
Bullard, Dis Colon rectum 2005, 48:438-43
Khoo, Surgery 2001, 130:463-9

www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

TIMING AND EXTENSION OF SURGERY FOR ANAL CANCER

- 1) CHEMO RADIATION
- 2) ASSESMENT OF RESPONSE 6-8 WEEKS
- 3) SALVAGE : LAPAROSCOPIC APR
- 4) RESECTION OF LEVATOR ANI
- 5) FLAP / PRIMARY CLOSURE

www.chirurgieviscerale.ch
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS